Navigation Links
Prism Pharmaceuticals to Receive $10 Million Milestone Payment from Paul Capital Healthcare
Date:1/8/2009

KING OF PRUSSIA, Pa., Jan. 8 /PRNewswire/ -- Prism Pharmaceuticals announced today that it will receive a $10 million milestone payment from Paul Capital Healthcare (formerly Paul Royalty Funds), the healthcare investment platform of Paul Capital. The milestone payment is triggered by the recent U.S. Food and Drug Administration (FDA) approval of Prism's new drug application (NDA) for NEXTERONE(R) (amiodarone HCl) Injection, a novel, patent-protected, cosolvent free formulation of the antiarrhythmic agent Amiodarone IV. The long range financing agreement with Paul Capital Healthcare, established in September 2006, provides Prism with non-dilutive capital to bring NEXTERONE through to commercial launch in the US.

The September 2006 financing secured up to $68 million in capital from Paul Capital Healthcare and Essex Woodlands Health Ventures Fund VI, through a combination of equity and a revenue interest financing, which is funded based on the satisfaction of certain predetermined milestones.

"The flexible, forward-looking provisions of the Revenue Interest Assignment Agreement structured between Prism and Paul Capital are demonstrating its true value in the current financing climate surrounding emerging biopharmaceutical companies," said Dr. Warren D. Cooper, President and CEO of Prism Pharmaceuticals. "Our financial circumstances and ongoing support enable us to remain wholly focused on execution of our business plan and leveraging the NDA approval of our first product."

"Our initial investment in Prism Pharmaceuticals was based on the great potential of the company's approach to an alternative formulation of amiodarone and other drugs, and our belief in management's ability to bring new products to the market," said Dr. Walter Flamenbaum, a partner at Paul Capital Healthcare. "The capital provided by our Revenue Interest Assignment Agreement - a form of "synthetic royalty" agreement - with
'/>"/>

SOURCE Prism Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
2. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
3. Prism glasses expand the view for patients with hemianopia
4. New Empire BlueCross BlueShield Prism Plans Offer Better Choice and Affordability for New York Small Group Market
5. Prism Pharmaceuticals Appoints Maurits Geerlings Vice President of Business Development
6. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
7. Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
8. Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals
9. MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009
10. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
11. Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 02, 2014 The Quantum ... Quantum Innovations, Inc . (QI), it has ... for MU2 Certification with a private IT security laboratory ... , The platform has Meaningful Use 1 certification status ... (7) approved and 15 pending patents. The accrediting organization ...
(Date:9/2/2014)... Kicking blog MichaelHusted.com is featuring an ... his role as a kicking coach, his kicking business, and ... to retired NFL kicker Michael Husted author of HustedKicking.com. , ... is one of the top pro free agent kickers out ... Anthony at our 2014 Pro Camp and I was impressed ...
(Date:9/2/2014)... 2 September 2014: The fact that mechanical heart valves ... by data from the ROPAC registry presented for the ... session by Professor Jolien W. Roos-Hesselink, co-chair with Professor ... found that 1.4% of pregnant women with a mechanical ... pregnancy. , The Registry Of Pregnancy And Cardiac disease ...
(Date:9/2/2014)... 02, 2014 “Harmonicas have been ... decade, primarily to help people with COPD or ... three developed systems,” says Dana Keller, PhD, co-inventor ... the goals are much the same – improved ... type of harmonica.” , The three approaches to ...
(Date:9/2/2014)... 2014 Fast hosting is a great ... compared many professional web hosting suppliers and announced that ... suppliers. , “It is hard to find a ... their competitors on hosting features, uptime, server speed and ... at affordable rates,” a manager of Top10BestSEOHosting.com says. , ...
Breaking Medicine News(10 mins):Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 2Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 4Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 5Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 3Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Top10BestSEOHosting.com Recommends Fast Web Hosting Suppliers 2
... and Manufacturing Plans Approved for Neuradiab(TM) Multi- center ... Clinical Trial ... TSX: ... the development and,commercialization of cancer therapies, today announced that it has received,notification from the ...
... June 3 When Brett Waslefsky,s wife,said her job ... a school,teacher, the stresses of the job, as well ... to stay healthy. With this casual,conversation, a new kind ... Employee Vita, a web-based vitamin company,that offers occupation specific ...
... childhood pneumococcal conjugate vaccine has been a boon in ... and the medical community must not get complacent, as ... rise, say scientists at a meeting today in Boston. ... the total burden of pneumococcal disease. It targets ...
... Cancer is the Number One Cause ... MAF Canine Cancer Campaign Seeking to Treat and Cure Dogs, DENVER, ... http://www.MorrisAnimalFoundation.org, a canine,cancer exclusive of special interest to dog owners ... the number one cause,of death in dogs over the age of two. ...
... To shed unwanted pounds,Americans, spend $46 billion ... and dietitians say merely choosing the right nutrient-dense,foods ... inflammation in our,bodies, and feel more energetic. But ... healthy ingredients we,re encouraged to buy. The article, ...
... asserts passage would strip illustrators of essential rights ... educational nonprofits, LAWRENCE, Kan., June 3 ... an international organization,representing highly trained professional medical illustrators ... Orphan Works Act,of 2008" (H.R. 5889/S. 2913), pending ...
Cached Medicine News:Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 2Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 3Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 4Health News:New Vitamin Company Caters to Occupational Health Concerns 2Health News:Despite vaccine, public should not get complacent about pneumococcal disease 2Health News:Canine Cancer Web Exclusive for Dog Owners and Lovers, Presented by Morris Animal Foundation - Features Colorado State and Cornell University Veterinary Cancer Experts 2Health News:Natural Solutions Names 45 Must-Have Foods for Healthy Weight Loss 2Health News:Association of Medical Illustrators Denounces 'Orphan Works' Bills Before Congress 2
(Date:8/29/2014)... DIEGO , Aug. 29, 2014   ... emerging biopharmaceutical company, announced today that Santosh Vetticaden, ... be leaving the Company, for personal reasons, in ... Chief Medical Officer of Aires Pharmaceuticals, which Mast ... former responsibilities as the Company,s interim Chief Medical ...
(Date:8/29/2014)... WEST JORDAN, Utah , Aug. 29, 2014 /PRNewswire/ ... Imaging Solutions, has acquired Polaris Medical Imaging, a leader ... CT scanners. This strategic acquisition allows BC Technical to ... their capabilities, specifically within MR and CT modalities. ... lower cost service," said Mark Alvarez , president ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4BC Technical Acquires Polaris Medical Imaging 2US CNS Disorders Drug Pipeline Insight 2014 2
... Reportlinker.com announces that a new market research ... Global Medical Laser Systems Industry ... This report analyzes the worldwide markets ... by the following Product Segments: Surgical Lasers, ...
... Reportlinker.com announces that a new market research ... Global Microscopes Industry ... report analyzes the worldwide markets for Microscopes ... Segments: Optical Microscopes, Charged Particle Microscopes, and ...
Cached Medicine Technology:Global Medical Laser Systems Industry 2Global Microscopes Industry 2
... CONMED's family of products allows you to ... generators feature proprietary Energy Synchronous Processing Technology. ... current and voltage in all operational modes. ... to sample current and voltage over 450,000 ...
... achieves a secure clot, targeted to the ... hemostasis is needed, when control of bleeding ... and cautery, is ineffective or impractical., CROSSEAL* ... of human Biologically Active Component (BAC) and ...
GluStitch® is indicated for the closure of uncomplicated skin lacerations where there is little or no tissue loss....
... pacemaker family offers some ... automatic devices. Featuring the ... advanced technologies ever seen, ... incorporates the exclusive ventricular ...
Medicine Products: